Core Insights - Incyte Corporation reported a Q4 2025 revenue increase of 28% to $1.51 billion, with full-year sales reaching $5.14 billion, driven primarily by Jakafi and Opzelura [1][7] Financial Performance - The company's core business, excluding Jakafi, experienced a 53% year-over-year growth in Q4 2025, with significant contributions from the hematology and oncology franchise, particularly Niktimvo and Monjuvi, which saw a 121% quarterly revenue surge [2] - Jakafi achieved annual sales of $3.093 billion, while the company anticipates a mid-single-digit sales increase for Jakafi in 2026 [3] Research and Development - Incyte's R&D efforts have matured, with timely regulatory submissions for Jakafi XR and povercinib, and management forecasts over 30% growth in core business as it aims for 14 pivotal clinical trials by year-end 2026 [2][3] Strategic Goals - The company aims to nearly double its business size through internal innovation and strategic business development, heavily investing in next-generation treatments such as its KRAS program and frontline DLBCL therapies [3] Market Position - Incyte Corporation is a biopharmaceutical company engaged in discovering, developing, and commercializing therapeutics across the US, Europe, Canada, and Japan, with collaborations and license agreements with major companies like Novartis, Lilly, and Syndax [4]